Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Michael Bogenstaetter as chief business officer

He joins the immuno-oncology biotech from Interim Assignments

Michael BogenstaetterNorwegian biotechTargovax has appointed its new chief business officer in the form of Michael Bogenstaetter, who joins following 25 years’ experience in the biotech and pharmaceutical industries.

Bogenstaetter previously served as an advisor of life sciences and health care at Interim Assignments, and before that he served as global head strategy, project management and operations drug discovery at Sanofi.

He has also held numerous roles for Novartis, MSD and Johnson and Johnson.

Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”

22nd January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...